India’s pharmaceutical industry supplies roughly 40 percent of the United States’ generic medicines and approximately 20 percent of global demand. Yet behind this impressive export footprint lies a structural vulnerability that the country’s own policy think tank, NITI Aayog, has recently brought into sharp focus: a heavy dependence on China for active pharmaceutical ingredients (APIs) and critical raw materials. For international buyers who rely on Indian generic medicines, understanding this supply chain dynamic is essential for long-term procurement strategy.
The NITI Aayog Warning: A Strategic Chokepoint
In a significant policy statement, NITI Aayog acknowledged that India’s pharmaceutical manufacturing ecosystem remains heavily dependent on Chinese imports for starting materials, intermediates, and APIs. This reliance creates a supply chain risk that policy analysts describe as a “strategic chokepoint” — one that was exposed during global supply disruptions and trade tensions in recent years.
The think tank’s assessment notes that while India has expanded its domestic API manufacturing capacity under the Production Linked Incentive (PLI) Scheme, a significant share of the country’s pharma raw material requirements still flows from Chinese manufacturers. Key antibiotic APIs, cardiovascular drug intermediates, and certain oncology precursors illustrate the continued import dependency.
What This Means for International Buyers
For procurement teams and importers sourcing from Indian manufacturers, the API supply chain concern translates into several practical considerations:
- Supplier transparency — Ask potential suppliers about their API source countries and whether they maintain dual-source or domestic API alternatives.
- Regulatory documentation — Verify that suppliers hold valid GMP certificates and can provide documentation of stable sourcing arrangements.
- Risk diversification — Avoid reliance on a single manufacturer for critical therapeutic categories; build a vetted supplier panel across multiple CDSCO-licensed facilities.
- Long lead-time awareness — API supply disruptions from source countries can extend manufacturing timelines. Build buffer stock or flexible contract terms where feasible.
India’s Response: Domestic API Manufacturing Push
The Indian government has responded to the import dependency concern with targeted incentives. Under the PLI Scheme for bulk drugs, financial incentives are offered to domestic API manufacturers, with the stated goal of reducing import reliance and enhancing supply chain security. Several large Indian pharma companies have announced investments in backward-integrated API manufacturing, bringing previously imported intermediates in-house.
CDSCO has also strengthened its oversight of manufacturing facilities, implementing tighter Good Manufacturing Practice (GMP) audits and third-party inspection regimes to ensure that domestic API production meets international quality standards. For buyers, this regulatory tightening supports higher confidence in Indian-sourced APIs, particularly when sourced from facilities with audited, verifiable compliance records.
Quality Implications of API Sourcing
API quality determines finished-dosage quality. Buyers who prioritise Indian generic medicines should verify that their chosen suppliers hold current WHO-GMP certification and can demonstrate consistent API provenance. The following quality markers indicate a reliable supplier:
- WHO-GMP certificate valid for the specific manufacturing site
- CDSCO manufacturing licence covering the relevant dosage forms
- Documented API sourcing policy with primary and secondary suppliers named
- Third-party audit reports (USP, MHRA, or CDSCO) available on request
For buyers seeking suppliers that meet these criteria, IMSDA’s verified member directory provides a curated list of manufacturers with audited export-compliance credentials. Gold members represent the highest tier of verified suppliers.
Source: NITI Aayog statements as reported in Deccan Herald and related Indian policy coverage, June 2026.
For queries, sourcing support, or membership information, contact us:
contact@indiamedicine.org